Singular Genomics Systems, Inc. (OMIC)
NASDAQ: OMIC · Real-Time Price · USD
22.50
+0.19 (0.85%)
Nov 5, 2024, 11:13 AM EST - Market open

Company Description

Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine.

The company is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection with high-definition sequencing, gene fusion detection with ring-seq, and extended range sequencing; and PX instrument and associated consumables focusing on the single cell and spatial analysis markets.

Singular Genomics Systems, Inc. was incorporated in 2016 and is based in San Diego, California.

Singular Genomics Systems, Inc.
Singular Genomics Systems logo
Country United States
Founded 2016
IPO Date May 27, 2021
Industry Medical Instruments & Supplies
Sector Healthcare
Employees 255
CEO Andrew Spaventa

Contact Details

Address:
3010 Science Park Road
San Diego, California 92121
United States
Phone 858 333 7830
Website singulargenomics.com

Stock Details

Ticker Symbol OMIC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $22.00
CIK Code 0001850906
CUSIP Number 82933R100
ISIN Number US82933R1005
Employer ID 81-2948451
SIC Code 3826

Key Executives

Name Position
Andrew Spaventa Founder, Chief Executive Officer, President and Chairperson of the Board
Dr. David L. Barker Ph.D. Founder, Member of Scientific Advisory Board and Independent Director
Dr. Eli N. Glezer Ph.D. Founder, Chief Scientific Officer and Chair of Scientific Advisory Board
Dalen Meeter Chief Financial Officer
Dr. Jyotsna Ghai Ph.D. Chief Operating Officer
Eric Stier Senior Vice President, General Counsel and Secretary
Jeff Bullard Head of Sales
Vincent Brancaccio Head of Human Resources
Jorge Velarde Jr., MBA Chief Business Officer

Latest SEC Filings

Date Type Title
Nov 4, 2024 8-K Current Report
Nov 1, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Sep 19, 2024 8-K Current Report
Sep 18, 2024 SC 13D General statement of acquisition of beneficial ownership
Sep 12, 2024 8-K Current Report
Sep 12, 2024 SC 13D General statement of acquisition of beneficial ownership
Aug 13, 2024 10-Q Quarterly Report
Aug 13, 2024 8-K Current Report
Aug 7, 2024 8-K Current Report
Jul 15, 2024 8-K Current Report